Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr135.70 SEK
Change Today +0.80 / 0.59%
Volume 723.2K
MEDAA On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
Berlin
OTC US
As of 12:30 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

meda ab-a shs (MEDAA) Snapshot

Open
kr134.80
Previous Close
kr134.90
Day High
kr136.10
Day Low
kr133.80
52 Week High
03/16/15 - kr140.00
52 Week Low
10/16/14 - kr85.61
Market Cap
49.6B
Average Volume 10 Days
685.2K
EPS TTM
kr1.37
Shares Outstanding
365.5M
EX-Date
05/7/15
P/E TM
98.9x
Dividend
kr2.50
Dividend Yield
1.78%
Current Stock Chart for MEDA AB-A SHS (MEDAA)

Related News

No related news articles were found.

meda ab-a shs (MEDAA) Related Businessweek News

No Related Businessweek News Found

meda ab-a shs (MEDAA) Details

Meda AB operates as a specialty pharmaceutical company worldwide. It manufactures and sells specialty pharmaceutical products, branded generics, over-the-counter drugs, and other products in various therapy areas, such as respiratory, dermatology, gastroenterology, cardiology, pain and inflammation, and CNS, as well as metabolism/vitamins. The company markets and sells its products through distributors in approximately 120 countries. Meda AB is headquartered in Solna, Sweden.

meda ab-a shs (MEDAA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2013.

meda ab-a shs (MEDAA) Key Developments

Meda AB Proposes Election of Kimberly Lein-Mathisen and Lillie Li Valeur as New Board Members

Meda AB announced that the nomination committee proposed the election of Kimberly Lein-Mathisen and Lillie Li Valeur as new board members. Kimberly has been CEO of Lilleborg within the Orkla Group for two years and she has 12 years of experience in senior international positions at Eli Lilly, among others as General Manager of the company's second large subsidiary, which is located in Germany. Kimberly is an external Board member of NHST Media Group. Lillie Li Valeur has been working for 13 years at Arla, and is now Vice President for South East Asia. She has previous experience in the pharmaceutical and OTC business from Novartis and Lundbeck. Lillie is an external Board member of AarhusKarlshamn AB. The appointments will be consider at the AGM to be held on May 6, 2015.

Meda Announces U.S. Food and Drug Administration Approval for Dymista Use in Patients 6-11 Years of Age

Meda announced the approval by FDA (U.S. Food and Drug Administration) of Dymista, a single formulation azelastine hydrochloride and fluticasone propionate nasal spray for the relief of symptoms of seasonal allergic rhinitis in patients 6-11 years of age who require treatment with both components. Dymista was previously indicated only for adults and children 12 and older. The approved dosing for Dymista in children 6 to 11 is 1 spray/nostril BID (same as the dosing for adolescents and adults with SAR). The efficacy and safety of Dymista was demonstrated in 2 pediatric trials where children 6 to 11 were treated with Dymista (1 spray per nostril twice daily). One of these trials was a two-week trial comparing efficacy of Dymista and placebo in 304 children 6 to 11 years of age with SAR. The other trial was a 12-week open-label trial comparing the safety of Dymista and fluticasone nasal spray in 353 children 6 to 11 years of age with allergic rhinitis.

Meda AB Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Meda AB reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Meda AB reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported operating loss of SEK 275 million against operating profit of SEK 258 million for the same period a year ago. Loss attributable to parent company shareholders was SEK 277 million against profit attributable to parent company shareholders of SEK 256 million for the same period a year ago. Net loss was SEK 275 million against net profit of SEK 258 million for the same period a year ago. EBITDA was SEK 1,012 million against SEK 1,015 million for the same period a year ago. Diluted earnings per share was SEK 1.46 against SEK 0.81 for the same period a year ago. Net sales were SEK 5,154 million against SEK 3,450 million for the same period a year ago. For the year, the company reported operating profit of SEK 1,487 million against SEK 1,548 million for the same period a year ago. Profit attributable to parent company shareholders was SEK 399 million against SEK 807 million for the same period a year ago. Net profit was SEK 402 million against SEK 805 million for the same period a year ago. EBITDA was SEK 3,990 million against SEK 3,734 million for the same period a year ago. Diluted earnings per share was SEK 3.64 against SEK 2.57 for the same period a year ago. Net sales were SEK 15,352 million against SEK 13,114 million for the same period a year ago. Return on equity, rolling 12 months was 2.2% against 5.4% for the same period a year ago. For 2015, The company expects sales of around SEK 20 billion (assuming current exchange rates) and an improved EBITDA margin compared to 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEDAA:SS kr135.70 SEK +0.80

MEDAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.113.40 CHF +0.80
Almirall SA €16.92 EUR +0.36
Ipsen SA €43.94 EUR +0.56
Orion Oyj €26.26 EUR -0.21
Recordati SpA €16.68 EUR -0.62
View Industry Companies
 

Industry Analysis

MEDAA

Industry Average

Valuation MEDAA Industry Range
Price/Earnings 99.9x
Price/Sales 2.8x
Price/Book 2.2x
Price/Cash Flow 112.9x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDA AB-A SHS, please visit www.meda.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.